Elinzanetant (BAY3427080)
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
Conditions
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
Trial Timeline
Oct 14, 2021 → Oct 19, 2022
NCT ID
NCT05071729About Elinzanetant (BAY3427080)
Elinzanetant (BAY3427080) is a phase 1 stage product being developed by Bayer for Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men. The current trial status is completed. This product is registered under clinical trial identifier NCT05071729. Target conditions include Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men.
What happened to similar drugs?
1 of 14 similar drugs in Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men were approved
Approved (1) Terminated (0) Active (13)
Hype Score Breakdown
Clinical
6
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05351892 | Phase 1 | Completed |
| NCT05071729 | Phase 1 | Completed |
Competing Products
20 competing products in Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men